Home Insights CNS indication/ Endpoint prioritization

CNS indication/ Endpoint prioritization

The challenge
  • A biopharma client with an early clinical stage compound, showing efficacy across multiple neuropsychiatric conditions, wished to prioritize indications for ongoing clinical development
Our solution
  • Through extensive primary/ secondary market research and literature review, we ranked each potential indication across multiple dimensions including epidemiology, burden of persistent unmet clinical need/ quality-of-life effects, complexity of standard clinical endpoints and symptom scores, likelihood of improvement, and on-market and pipeline competitive intensity
The results
  • Highest ranking diseases (and respective endpoints) were prioritized by the Clinical Development and Medical Affairs teams for incorporation into the ongoing clinical trial program